These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8889285)

  • 21. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in the dopaminergic response during the day in Parkinson disease.
    Monge A; Viselli F; Stocchi F; Barbato L; Bolner A; Modugno N; Paradiso M; Ruggieri S; Nordera G
    Clin Neuropharmacol; 2004; 27(3):116-8. PubMed ID: 15190233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST; Woodward WR; Nutt JG
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation.
    Brambilla F; Bellodi L; Perna G; Arancio C; Bertani A
    Biol Psychiatry; 1997 Nov; 42(10):889-97. PubMed ID: 9359974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression.
    McPherson H; Walsh A; Silverstone T
    J Affect Disord; 2003 Sep; 76(1-3):121-5. PubMed ID: 12943941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV; Katunina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
    [No Abstract]   [Full Text] [Related]  

  • 29. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment.
    Goldstein DS; Eldadah BA; Holmes C; Pechnik S; Moak J; Saleem A; Sharabi Y
    Hypertension; 2005 Dec; 46(6):1333-9. PubMed ID: 16216982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood pressure and heart rate in parkinsonian patients with and without wearing-off.
    Pursiainen V; Korpelainen JT; Haapaniemi TH; Sotaniemi KA; Myllylä VV
    Eur J Neurol; 2007 Apr; 14(4):373-8. PubMed ID: 17388983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
    Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
    Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
    Stryjer R; Klein C; Treves TA; Rabey JM
    Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease.
    Geffe S; Schindlbeck KA; Mehl A; Jende J; Klostermann F; Marzinzik F
    J Neural Transm (Vienna); 2016 Jun; 123(6):601-10. PubMed ID: 27106907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum prolactin levels in Parkinson's disease and multiple system atrophy.
    Winkler AS; Landau S; Chaudhuri KR
    Clin Auton Res; 2002 Oct; 12(5):393-8. PubMed ID: 12420085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side-effects of L-dopa on venous tone in Parkinson's disease: a leg-weighing assessment.
    Wolf JP; Bouhaddi M; Louisy F; Mikehiev A; Mourot L; Cappelle S; Vuillier F; Andre P; Rumbach L; Regnard J
    Clin Sci (Lond); 2006 Mar; 110(3):369-77. PubMed ID: 16302846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.